Background. About 5.7 million individuals in the United States have heart failure, and the disease was estimated to cost about $42.9 billion in 2020. This research provides geographical incidence models of this disease in the U.S. and explanatory models to account for hospitals’ number of heart failure DRGs using technical, workload, financial, geographical, and time-related variables. The research also provides updated financial and demand estimates based on inflationary pressures and disease rate increases. Understanding patterns is important to both policymakers and health administrators for cost control and planning. Methods. Maps of heart failure diagnosis-related groups (DRGs) from 2016 through 2018 depicted areas of high incidence as well as changes. Spatial regression identified no significant spatial correlations. Simple expenditure forecasts were calculated for 2016 through 2018. Linear, lasso, ridge, and Elastic Net models as well as ensembled tree regressors including were built on an 80% training set and evaluated on a 20% test set. Results: The incidence of heart failure has increased over time with highest intensities in the East and center of the country; however, several Northern states (e.g., Minnesota) have seen large increases in rates from 2016. The best traditional regression model explained 75% of the variability in the number of DRGs experienced by hospital using a small subset of variables including discharges, DRG type, percent Medicare reimbursement, hospital type, and medical school affiliation. The best ensembled tree models achieved R2 over .97 on the blinded test set and identified discharges, percent Medicare reimbursement, hospital acute days, affiliated physicians, staffed beds, employees, hospital type, emergency room visits, medical school affiliation, geographical location, and the number of surgeries as highly important predictors. Conclusions. Overall, the total cost of the three DRGs in the study has increased approximately $61 billion from 2016 through 2018 (average of two estimates). The increase in the more expensive DRG (DRG 291) has outpaced others with an associated increase of $92 billion in expenditures. With the increase in demand (linked to obesity and other factors) as well as the relatively steady-state supply of cardiologists over time, the costs are likely to balloon over the next decade.